Elotuzumab is a humanized IgG1-κ immunostimulatory MAb targeting signaling lymphocytic activation molecule F7 (SLAMF7), also referred to as cell-surface glycoprotein CD2 subset1 (CS1) which is expressed on MM cells and natural killer cells. Here, SLAMF7 is linked to Miyoshi myopathy.